About trastuzum ab deruxteca
HER2-targeted antibody-drug conjugate
Used for
- HER2-positive breast cancer
- HER2-low breast cancer
- HER2-positive gastric or gastroesophageal junction cancer
- Other eligible HER2-expressing solid tumors
Usual adult dose
Usually 5.4 mg/kg intravenously every three weeks for breast cancer; other cancers may use different doses.
Common side effects
- Nausea, vomiting, fatigue, and hair loss
- Low blood counts, especially neutrophils
- Diarrhea, constipation, or reduced appetite
- Interstitial lung disease or pneumonitis
Important warnings
- Can cause severe, potentially fatal lung inflammation; new cough or breathlessness requires urgent assessment.
- Can cause severe embryo-fetal harm; pregnancy testing and effective contraception are required.
- Monitor blood counts and heart function during treatment.
- Infusion reactions can occur; administer under specialist supervision.
Pregnancy
May harm an unborn baby. Avoid during treatment and for seven months after the last dose.
Breastfeeding
Breastfeeding is not recommended during treatment or for seven months after the last dose.
Interactions
- No major interactions are consistently established; provide the oncology team a complete medicines and supplement list.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.